Tirapazamine (TPZ) is a hypoxia activated drug that may be synergistic with transarterial embolization (TAE). The primary objective was to evaluate the safety of combining TPZ and TAE in patients with unresectable HCC and determine the optimal dose for Phase II. This was a Phase 1 multicenter, open-label, non-randomized trial with a classic 3+3 dose escalation and an expansion cohort in patients with unresectable HCC, Child Pugh A, ECOG 0 or 1. Two initial cohorts consisted of I.V. administration of Tirapazamine followed by superselective TAE while the remaining three cohorts underwent intraarterial administration of Tirapazamine with superselective TAE. Safety and tolerability were assessed using NCI CTCAE 4.0 with clinical, imaging and laboratory examinations including pharmacokinetic (PK) analysis and an electrocardiogram 1 day pre-dose, at 1, 2, 4, 6, 10, and 24 hours post-TPZ infusion and an additional PK at 15- and 30-minutes post-TPZ. Tumor responses were evaluated using mRECIST criteria. Twenty-seven patients (mean[range] age of 66.4 [37-79] years) with unresectable HCC were enrolled between July 2015 and January 2018. Two patients were lost to follow-up. Mean tumor size was 6.53 cm ± 2.60 cm with a median of two lesions per patient. Dose limiting toxicity and maximum tolerated dose were not reached. The maximal TPZ dose was 10 mg/m I.V. and 20 mg/m I.A. One adverse event (AE) was reported in all patients with fatigue, decreased appetite or pain being most common. Grade 3-5 AE were hypertension and transient elevation of AST/ALT in 70.4% of patients. No serious AE were drug related. Sixty percent (95% CI=38.7-78.9) achieved complete response (CR), and 84% (95% CI=63.9-95.5) had complete and partial response per mRECIST for target lesions. TAE with TPZ was safe and tolerable with encouraging results justifying pursuit of a Phase II trial.TAE with TPZ was safe and tolerable with encouraging results justifying pursuit of a Phase II trial.The reinfection of recovered COVID-19 patient is one of the major concerns worldwide. Here we report a case of previously recovered patient from Covid-19 who presented with symptomatic reinfection beyond 3 months. We report a case of 58 year old female patient who after presenting with symptomatic episode of RT-PCR confirmed COVID-19 in April 2020, presented with a new symptomatic infection by SARS-CoV-2 four months later. These 2 episodes of infection were caused by different sources as evident from her epidemiological correlates. This is the first epidemiologically, RAT, RT-PCR and antibody confirmed COVID-19 case of re-infection of SARS CoV-2 reported from Western India.Measurement of 24-h urine protein (UP) is the standard method for detection of proteinuria in preeclampsia (PE). A 24-h urine sampling is time-consuming, inconvenient, and delays the diagnosis of PE. A 29-year-old woman, previous cesarean section (CS), pregnant 37 weeks'+2 days, mild PE, and another 31-year-old woman, primipara, pregnant 34 weeks'+4 days, severe PE, were admitted for control of blood pressure and termination of pregnancy. Studied women were subjected to fetal well-being assessment, routine antenatal, and laboratory investigations to exclude chronic renal diseases, and for 24-h urine sampling. A spot mid-stream urine sample was obtained shortly before the 24-h urine sampling to measure the protein/creatinine (P/C) ratio. The first studied woman had normal serum creatinine and blood urea, 688 mg protein/24-h urine, 86 mg/dL spot UP, 178 mg/dL spot urine creatinine, and 0.48 P/C ratio. The second studied woman had also normal serum creatinine and blood urea, 1199 mg protein/24-h urine, 147 mg/dL spot UP, 133 mg/dL spot urine creatinine, and 1.11 spot P/C ratio. The spot urine sample was suggested by the National Kidney Foundation to detect and monitor proteinuria in adults. Moreover, the 24-h UP can be calculated from the following equation 24-h UP in g = P/C ratio × 0.81 + 0.3 (Abdelazim equation) without 24-h urine sampling. This report suggests the use of Abdelazim equation (24-h UP in g = P/C ratio × 0.81 + 0.3) for detection of 24-h UP from spot urine sample in PE without 24-h urine sampling.The recent pandemic of SARS COV-2, a novel coronavirus requires research into understanding of its transmission dynamics and clinical presentations to help in understanding the spread of the disease, how to prevent it not only locally but also for national policy formulations. In this study, we described the transmission dynamics and clinical presentations of a cluster outbreak of SARS COV-2 in a tertiary level hospital. We also calculated the secondary attack rate for the primary, secondary, and tertiary transmissions. We conclude that symptomatic COVID-19 are primary and secondary contacts rather than tertiary contacts, hence, former to be quarantined. However, tertiary transmission is causing more COVID-19 compared to other transmissions in a hospital outbreak without further transmissibility. And overall secondary attack rate is very low in a hospital outbreak. Research in health care system plays an important role in advancement and development of medicine and is essential in identifying the most optimal management. Progression in medicine depends upon the training and performance of researchers in health science. Isoprenaline Training in research activity is an important aspect of post graduate training and has been recognized as one of its key components. It enhances learning and critical thinking of the resident. A purposely constructed questionnaire was used to gather the data, questionnaire was composed on demographic items, items related to the problems/difficulties regarding research, items related to specialty selection. Questionnaire was composed of by the panel of experts including subject (research faculty of the college) specialist, English language expert, family physician. Mean ± S.D of age = 29.2 ± 8.6. 62.0% of the respondents were belongs to the age group of 25-30 years old, 22.% belongs to the 31-35 years old. 44.1% were female while 55.9% were male. Only 13.0% of the respondents finished the residency program (17.1% in R1, 25.7% in R2, 21.6% in R3, 13.6% in R4 while 2.5% in R5 and 6.7% as an adhoc). 51.6% have experience of healthcare from 1 to 3 years. 31.3% respondents participated in the research as a co-author while 26.3% participated in a research as principal investigator. To conclude, it is necessary to guide the students to conduct studies and keep them motivated. It is also important to reward them so keep their interest intact in research. In this view involving students in research committee and providing them a platform for presentation are very good methods to keep them motivated.To conclude, it is necessary to guide the students to conduct studies and keep them motivated. It is also important to reward them so keep their interest intact in research. In this view involving students in research committee and providing them a platform for presentation are very good methods to keep them motivated.